[A20-30] Riociguat (CTEPH) - Benefit assessment according to §35a Social Code Book V

Last updated 15.06.2020

Project no.:

Commission awarded on 17.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Heart and circulation


Adults with chronic thromboembolic pulmonary hypertension (CTEPH) with WHO Functional Class II to III to improve exercise capacity. The CTEPH has to be inoperable or persistent or recurrent after surgical treatment.

Result of dossier assessment:

Added benefit not proven due to lack of suitable study data


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.